Does PEGASUS need a COMPASS to find optimal medical management? – reviewing options in high risk CVD patients

“The quality of what Pharmacy Management is putting on is simply streets ahead of anything else I’m seeing at the moment. Keep up the good work!”
Noel Wicks, Managing Director, Right Medicine Pharmacy Ltd, Stirling
Satellite Does PEGASUS need a COMPASS to find optimal medical management? – reviewing options in high risk CVD patients
Speakers Paul Wright (Lead Cardiac Pharmacist - Cardiac Pharmacy Department, Barts Heart Centre, Barts Health NHS Trust)
Satellite Description

This session will touch of current practice for treatment options for those at high risk of CVD.  We will explore previous trial data looking at extending DAPT therapy and explore new options – predominantly data for rivaroxaban 2.5mg twice daily (in the COMPASS trial) and from ticagrelor 60mg twice daily (from the PEGASUS trial).  Finally we will explore options on how these strategies could be implemented at a local level.

Advanced level – knowledge of ACS and current treatment strategies required

Back to Course

Connect with us Industry NHS

Confirmation

This site is intended for healthcare professionals or people employed in the pharmaceutical industry. Please confirm that you are such a person.

Continue